DermTech (DermTech) Accounts Receivable : $2.50 Mil (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is DermTech Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. DermTech's accounts receivables for the quarter that ended in Mar. 2024 was $2.50 Mil.

Accounts receivable can be measured by Days Sales Outstanding. DermTech's Days Sales Outstanding for the quarter that ended in Mar. 2024 was 59.26.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. DermTech's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was $-0.62.

DermTech Accounts Receivable Historical Data

The historical data trend for DermTech's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DermTech Accounts Receivable Chart

DermTech Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Dec20

Dec21

Dec22

Dec23

Accounts Receivable

Get a 7-Day Free Trial

1.48

3.85

4.17

2.58

DermTech Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Receivable	Get a 7-Day Free Trial															3.69	3.87	3.61	2.58	2.50

DermTech Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

DermTech Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

DermTech's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	2.497	/	3.845	*	91
=	59.26

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), DermTech's accounts receivable are only considered to be worth 75% of book value:

DermTech's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(38.979	+	0.75 * 2.497	+	0.5 * 0.831	-	62.976
-	0	-	0)	/	34.963
=	-0.62

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

DermTech Accounts Receivable Related Terms

Thank you for viewing the detailed overview of DermTech's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

DermTech (DermTech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » DermTech Inc (NAS:DMTK) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

N/A

Address

11099 N. Torrey Pines Road, Suite 100, La Jolla, CA, USA, 92037

Website

https://www.dermtech.com

DermTech Inc is an emerging growth molecular diagnostic company. The company is engaged in marketing and developing novel non-invasive genomic tests to aid in the diagnosis of various skin conditions, including skin cancer, inflammatory diseases, and aging-related conditions. While the company generates revenue through laboratory services.

Executives

Kevin M Sun	officer: Chief Financial Officer	6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Claudia Ibarra	officer: Chief Operating Officer	C/O DERMTECH, INC., 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Ramin Akhavan	officer: General Counsel	C/O DERMTECH, INC., 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Mark Bryan Aguillard	officer: Chief Commercial Officer	19800 CORDILL LANE, SPICEWOOD TX 78669
Todd Michael Wood	officer: Chief Commercial Officer	C/O OBALON THERAPEUTICS, INC., 5421 AVENIDA ENCINAS, SUITE F, SAN DIEGO CA 92008
Bret Christensen	director, officer: Chief Executive Officer	600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
John Dobak	director, officer: Chief Executive Officer	11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Rtw Investments, Lp	10 percent owner	40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Kirk Malloy	director	5200 ILLUMINA WAY, SAN DIEGO CA 92122
Mark Christopher Capone	director	320 WAKARA WAY, SALT LAKE CITY UT 84108
Herm Rosenman	director	OXFORD IMMUNOTEC GLOBAL PLC, 94C INNOVATION DRIVE, HILTON PARK, SAN DIEGO X0 OX14 4RZ
Nathalie Gerschtein Keraudy	director	C/O DERMTECH, INC., 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Monica Tellado	director	C/O DERMTECH, INC., 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Enrico Picozza	director	11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Matthew L. Posard	director	11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037